|
Published by: Frost & Sullivan
Published: Mar. 14, 2003
Table of Contents
1. Executive Summary
A. Executive Summary
1. Executive Summary
2. Introduction
A. Overview
1. Scope and Segmentation
2. Disease Definition
3. Risk Factors
4. Disease Classification
5. Treatment
6. Drug Delivery Methods
7. Societal Economic Burden
8. Challenges and Strategies
9. Drivers
10. Restraints
B. Market Dynamics
1. Demand Analysis
2. Market and Technology Trends
3. Total Market Revenue Forecast
4. Market Share Analysis
C. Frost & Sullivan Market Engineering Awards
1. Market Leadership Award
2. Strategic Alliance Leadership Award
3. Brand Awareness Development Award
4. Business Development Strategy Award
5. Technology Innovation Award
3. Bronchodilator Therapies Market
A. Overview
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
B. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
C. Short-Acting Beta2 Agonist Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
8. Product Analysis-Emerging
D. Long-Acting Beta2 Agonist Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
8. Product Analysis-Emerging
E. Anticholinergics Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
F. Methylxanthines Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Product Analysis-Existing
4. Anti-Inflammatory Therapies Market
A. Overview
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
B. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
C. Inhaled Corticosteroid Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
8. Product Analysis-Emerging
D. Mediator-Release Inhibitor Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
E. Anti-Leukotriene Market
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
5. Competitive Structure
6. Market Share Analysis
7. Product Analysis-Existing
8. Product Analysis-Emerging
F. Other Emerging Anti-Inflammatory Therapies Market
1. Introduction
2. Revenue Forecast
3. Competitive Structure
4. Product Analysis-Emerging
5. Bronchodilator/Corticosteroid Combination Therapies Market
A. Overview
1. Introduction
2. Market Engineering Analysis
3. Revenue Forecast
4. Pricing Trends
B. Competitive Analysis
1. Competitive Structure
2. Market Share Analysis
3. Product Analysis-Existing
4. Product Analysis-Emerging
6. Other Emerging Asthma Therapies Market
A. Overview
1. Introduction
2. Competitive Structure
3. Product Analysis-Emerging
AbstractGrowing Penetration of Combination Drugs Spur Growth
The unprecedented success of GlaxoSmithKline's bronchodilator-corticosteroid combination drug, Advair, is changing the landscape of the U.S. asthma therapies market. As physicians become more comfortable with the long-term safety of Advair, few patient groups will remain off limits for this drug, which is already being used far widely than originally anticipated. "Future revenue growth lies in the growing adoption of Advair, and potentially other bronchodilator-corticosteroid combination drugs, such as AstraZeneca's Symbicort (budesonide-formoterol), at the expense of single-agent asthma drugs," says the analyst.
This Frost & Sullivan research analyzes the U.S. asthma therapies markets, divided into four main segments: bronchodilators, anti-inflammatories, bronchodilator-corticosteroid combinations, and other emerging therapies. It provides detailed insights into recent developments, trends, and emerging applications. This study also includes market forecasts and competitive and opportunity analysis.
Growing Acceptance of Dry Powder Inhaler Delivery Systems
The growing franchise of dry powder inhalers (DPIs) is posing a threat to the position of metered-dose inhalers (MDIs) in the future treatment of asthma. The rapid acceptance of DPIs is driven by its ease and convenience of use and potentially better drug deposition, compared with MDIs. Also, strict regulations governing the reformulation of older CFC-containing MDIs into hydrofluoroalkane (HFA) containing MDIs are boosting growth in the DPI market.
Newer Classes of Drugs Pave the Way for Long-term growth
Companies that develop new drugs to address unmet medical needs and position them suitably are guaranteed revenue success. Drug developers focus on new drugs with improved efficacy, longer duration of action and reduced frequency of dosing, more convenient administration, better safety, multiple mechanisms of action and/or disease-modifying capabilities. "The impact of novel product classes that address the underlying causes of asthma, such as monoclonal antibodies, phosphodiesterase-IV inhibitors, and alpha4 integrin antagonists, may be significant in the long term," says the analyst of this study.
Get Full Details About This Report >>
|
